NICE Says No To Celgene's Vidaza
This article was originally published in Scrip
NICE, England's health technology appraisal institute has said no to Celgene's Vidaza (azacitidine) for some NHS patients with acute myeloid leukemia. Among NICE's concerns was Vidaza's effectiveness compared with conventional care.
Register for our free email digests: